WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) — Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following investor conferences in November.
- Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 12:40 p.m. GMT in London
- Barclays Gene Editing & Gene Therapy Summit on Thursday, November 29, 2018 at 8:30 a.m. ET in New York City
The presentation at the Jefferies London Healthcare Conference will be webcast. To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for two weeks following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in Nature Medicine in 2018, in The New England Journal of Medicine in 2016, and in The Lancet in 2014. Nightstar’s second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. In September 2018, Nightstar announced preliminary safety and efficacy data from the XIRIUS trial for the first five cohorts (combined n=15) of the dose escalation study at the EURETINA medical meeting.
For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.
Contact:
Senthil Sundaram, Chief Financial Officer
Brian Luque, Sr. Manager, Investor Relations
[email protected]
